JAPhA Practice Innovations最新文献

{"title":"Evaluating the impact of pharmacist-delivered educational intervention on the willingness to receive HPV vaccine in a dental clinic in New York","authors":"Julian Azzouzi ,&nbsp;Joanne Son ,&nbsp;Katrin Tamari ,&nbsp;Eric Wachs ,&nbsp;Elizabeth J. Unni","doi":"10.1016/j.japhpi.2025.100053","DOIUrl":"10.1016/j.japhpi.2025.100053","url":null,"abstract":"<div><h3>Background</h3><div>Human papillomavirus (HPV) infections are the leading cause of oral and oropharyngeal cancers in the United States, accounting for 70% of new diagnoses. An estimated 90% of newly diagnosed HPV-attributed cancer cases could be preventable with HPV vaccination before exposure, given that the vaccine is 100% effective for at least 12 years. Collaboration between dentists and pharmacists to enhance patient-centered care and vaccine education holds considerable potential to increase HPV vaccine rates among persons aged 9-26 years. Current literature exploring interprofessional collaboration between dentists and pharmacists suggests this partnership may address gaps in patient care, although examples of HPV vaccine initiatives are limited.</div></div><div><h3>Objective</h3><div>This study aimed to assess the impact of screening dental patients’ HPV vaccine status and providing pharmacist-led education and counseling on the intent of patients or guardians to receive the HPV vaccine.</div></div><div><h3>Methods</h3><div>Approved by the institutional review board, a cross-sectional prospective review of patients was conducted at a dental clinic. Patients aged 18-26 years and those aged 9-17 with consenting guardians who had not received the HPV vaccine, verified via the New York State Immunization Information System, were included. Enrolled participants received pharmacist-led education and counseling on HPV and the vaccine, including an educational handout. After the intervention, participants were surveyed to assess their interest in receiving the HPV vaccine. Statistical analysis used a 1-sample proportion test.</div></div><div><h3>Results</h3><div>A total of 67 patients and guardians were approached after prospective review, 32 agreed to participate, 13 were excluded, and a total of 19 were enrolled in the study. After pharmacist intervention, the proportion of participants’ intent to receive the HPV vaccine was 0.895 (<em>P</em> &lt; .001; 95% CI, 0.76–1.00).</div></div><div><h3>Conclusion</h3><div>Screening dental patients’ HPV vaccine status, paired with pharmacist-delivered HPV education and HPV vaccine counseling, may positively affect unvaccinated patients’ or guardians’ intent to receive the HPV vaccine.</div></div>","PeriodicalId":100737,"journal":{"name":"JAPhA Practice Innovations","volume":"2 3","pages":"Article 100053"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144631588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of a Drug Take Back Day event at a large chain community pharmacy","authors":"Kayla Pangilinan,&nbsp;Jessica McDaniel,&nbsp;Pramit Nadpara,&nbsp;Jean-Venable R. Goode","doi":"10.1016/j.japhpi.2025.100042","DOIUrl":"10.1016/j.japhpi.2025.100042","url":null,"abstract":"<div><h3>Background</h3><div>Medication accumulation is a growing public health concern associated with misuse, overdose, pollution, and wasted health care expenditures. Mitigation strategies such as Drug Take Back Day remain underutilized owing to a lack of awareness and access.</div></div><div><h3>Objectives</h3><div>This study aimed to analyze the quantity and characteristics of medications collected, assess donor knowledge and attitudes on safe medication disposal and reasons for medication accumulation, identify patient education opportunities, and compare data collected at 2 drug take back site locations.</div></div><div><h3>Methods</h3><div>Descriptive cross-sectional study conducted at 2 Drug Take Back Day events hosted by a large chain community pharmacy, 1 urban and 1 suburban. Disposed medication characteristics were recorded for the urban site only owing to restrictions from law enforcement, including product name, strength, dosage form, route of administration, category, drug class, length of treatment, condition, and controlled substance schedule. The number of donors and education brochures distributed was tracked, and medications were weighed at conclusion. A 17-question survey was offered to donors 18 years or older to assess demographics, characteristics of disposed medications, and knowledge and attitudes on safe medication disposal. Descriptive statistics were used to analyze results.</div></div><div><h3>Results</h3><div>A total of 311 medications were collected at the urban site. Most were expired noncontrolled prescriptions including supplements and vitamins, analgesics, and cardiovascular drugs. Forty of 246 donors completed the survey. The most identified reasons for excess medication were patient’s death, “excessive quantity,” and medication discontinuation. Eighty percent considered environmental concerns, 48% diversion prevention, and 30% fear of addiction or dependence reasons for participation. Twenty-one donors disposed of 67.8 pounds and 225 donors disposed of 600.9 pounds of medications, with 108 and 250 educational brochures distributed at urban and suburban sites, respectively.</div></div><div><h3>Conclusion</h3><div>Medications collected at Drug Take Back Day were expired noncontrolled prescriptions. Donors valued the environment and poison prevention over diversion and addiction concerns.</div></div>","PeriodicalId":100737,"journal":{"name":"JAPhA Practice Innovations","volume":"2 3","pages":"Article 100042"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144631650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of GLP-1 agonists vs. other weight management medications in obese and overweight patients","authors":"Arielle Davidson,&nbsp;Christina Inteso,&nbsp;Nolan Rossman,&nbsp;Toni Larson,&nbsp;Kathryn Dudzinski","doi":"10.1016/j.japhpi.2025.100046","DOIUrl":"10.1016/j.japhpi.2025.100046","url":null,"abstract":"<div><h3>Background</h3><div>Glucagon-like peptide-1 (GLP-1) agonists are efficacious for weight management; however, there are barriers that prevent access. Although studies have shown the efficacy of individual treatments, there is a lack of evidence that compares different classes of weight management medications with each other.</div></div><div><h3>Objective</h3><div>This study aimed to compare the efficacy of GLP-1 agonists with other classes of weight management medications.</div></div><div><h3>Methods</h3><div>This retrospective chart review included patients prescribed a weight management medication by a primary care pharmacist at Corewell Health between June 1, 2022, and June 1, 2023. Patients were assigned to (1) the GLP-1 agonist group or (2) the non-GLP-1 agonist group. The primary outcome was the percentage of patients who reached ≥ 5% weight loss at the end of the treatment course. The secondary outcomes include the percentage of patients who reached ≥ 10% weight loss and ≥ 15% weight loss at the end of the treatment course and average change in body mass index (BMI) at the end of the treatment course.</div></div><div><h3>Results</h3><div>A higher number of patients in the GLP-1 agonist group achieved the primary end point of ≥ 5% weight loss compared with the non-GLP-1 agonist group (29 patients [50.9%] vs. 17 patients [30.9%], <em>P</em> = 0.0318). A logistic model was done, which showed that, when accounting for medication duration, the number of patients in the GLP-1 agonist group who reached the primary end point was not statistically significant compared with the non-GLP-1 agonist group with a <em>P</em> value of 0.0772. There was not a statistically significant difference in the number of patients who achieved ≥ 10% and ≥ 15% weight loss between groups, whereas BMI change was statistically significantly greater in the GLP-1 agonist group.</div></div><div><h3>Conclusion</h3><div>A higher percentage of patients in the GLP-1 agonist group reached ≥ 5% weight loss as compared to patients in the non-GLP-1 agonist group, without regard to medication duration.</div></div>","PeriodicalId":100737,"journal":{"name":"JAPhA Practice Innovations","volume":"2 3","pages":"Article 100046"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144631653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The evaluation of treatment of chlamydia and gonorrhea in the emergency department at a military treatment facility","authors":"Carlo Tiano,&nbsp;Kayla Scheps,&nbsp;Amber Brammer","doi":"10.1016/j.japhpi.2025.100047","DOIUrl":"10.1016/j.japhpi.2025.100047","url":null,"abstract":"<div><h3>Background</h3><div>Sexually transmitted infections (STIs) have a major impact on global sexual and reproductive health. A systematic review of 13 studies involving emergency department (ED) patients who were tested and empirically treated for <em>Neisseria gonorrhoeae</em> (NG), <em>Chlamydia trachomatis</em> (CT), or both before receiving their nucleic acid amplification test results revealed that up to 84% of patients with positive test results were ultimately undertreated. Addressing this discrepancy is crucial for enhancing the quality of care for patients.</div></div><div><h3>Objective</h3><div>This study aimed to evaluate the impact of pharmacist-led interventions on the incidence of guideline-concordant empirical treatment for chlamydia and gonorrhea in patients presenting to the ED at a large academic military treatment facility (MTF).</div></div><div><h3>Methods</h3><div>A retrospective chart review was conducted at a large academic MTF ED from June 1, 2023, to September 30, 2023. Adult patients screened and treated for CT and NG were included. The primary outcome measured the percentage of patients who received empirical guideline-concordant treatment. Secondary outcomes included the number of patients untreated in the ED, patients who returned for treatment, and those lost to follow-up. After baseline data collection, a pharmacy-led in-service was conducted with educational handouts and education regarding the creation of an STI order set. A postintervention analysis was conducted from February 13, 2024, to April 30, 2024. Data were analyzed with descriptive statistics and chi-squared tests for categorical associations and means and SD for parametric data.</div></div><div><h3>Results</h3><div>In the preintervention group, 108 of 304 screened patients met inclusion criteria; 64 patients (59%) received concordant empirical treatment. After the intervention, 52 of 58 included patients (90%) received guideline-concordant treatment, showing a statistically significant improvement (<em>P</em> &lt; 0.001). Inappropriate treatment duration and dosage were common preintervention issues. After the intervention, adherence to guidelines improved, reducing inappropriate treatment cases.</div></div><div><h3>Conclusion</h3><div>A notable proportion of patients initially received inappropriate treatment. Implementing clinician education and order sets significantly improved compliance with treatment guidelines, demonstrating the effectiveness of targeted quality improvement initiatives.</div></div>","PeriodicalId":100737,"journal":{"name":"JAPhA Practice Innovations","volume":"2 3","pages":"Article 100047"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144631654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of a hybrid heart failure clinic model on optimization of guideline-directed medical therapy","authors":"Matthew Aludino,&nbsp;Jasmine Stinson,&nbsp;Mark Bounthavong,&nbsp;Jennifer Namba,&nbsp;Trina Huynh,&nbsp;Andrew Willeford","doi":"10.1016/j.japhpi.2025.100056","DOIUrl":"10.1016/j.japhpi.2025.100056","url":null,"abstract":"<div><h3>Background</h3><div>Achieving rapid titration of guideline-directed medical therapy (GDMT) for patients with heart failure may be challenging due to limited clinical resources.</div></div><div><h3>Objective</h3><div>This study aimed to evaluate the effectiveness of a hybrid clinic model led by pharmacists in optimizing GDMT.</div></div><div><h3>Methods</h3><div>A single-center, retrospective analysis compared patients with an ejection fraction &lt; 50% seen in a hybrid clinic model that included multidisciplinary in-person visits and pharmacist-led telehealth appointments (hybrid) to an in-person model that included only a cardiology provider (historical). The primary end point was the number of GDMT medications prescribed per patient. An exploratory end point included a modified optimal medical therapy score (mOMT). Outcomes were analyzed using a linear mixed-effects model adjusting for baseline characteristics.</div></div><div><h3>Results</h3><div>Patients in the hybrid cohort (n = 52) increased from 2.5 to 3.1 GDMT at 3 months compared to 2.5 to 2.8 in the historical cohort (n = 46). There was a significantly greater increase in the average number of GDMT at each time interval in the hybrid cohort compared to the historical cohort (difference in changes per interval = +0.13; 95% CI: 0.05, 0.21). More patients were on quadruple therapy at the last study visit (48.1% vs 26.1%, <em>P</em> = 0.025), and the increase in mOMT was significantly higher in the hybrid cohort (difference in changes = +0.036; 95% CI: 0.015, 0.056).</div></div><div><h3>Conclusions</h3><div>The hybrid model involving pharmacists was associated with greater initiation of GDMT compared to in-person care without a pharmacist. This study confirms the valuable role of pharmacists in optimizing therapy for patients with heart failure.</div></div>","PeriodicalId":100737,"journal":{"name":"JAPhA Practice Innovations","volume":"2 4","pages":"Article 100056"},"PeriodicalIF":0.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144570383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing evidence-based decision making through primary care provider–pharmacist collaboration and patient simulation training","authors":"Adam Chesler,&nbsp;Jessica Puckett-Beasley,&nbsp;Amir Shakouri,&nbsp;Michelle Borowski,&nbsp;David Eustis,&nbsp;David Paculdo,&nbsp;Isabella Cooney,&nbsp;John Paulo Vergara,&nbsp;Clive Fields,&nbsp;Trever Burgon","doi":"10.1016/j.japhpi.2025.100031","DOIUrl":"10.1016/j.japhpi.2025.100031","url":null,"abstract":"<div><h3>Background</h3><div>Traditionally, physicians’ and pharmacists’ roles have been distinct. However, an aging population, increasing prevalence of chronic conditions, the growth of value-based care payments, and forecasted shortfalls in primary care providers (PCPs) are forcing a rethinking of this paradigm. Creating opportunities for collaboration between PCPs and pharmacists presents an opportunity to address these challenges. This study explores the impact of this collaboration on evidence-based decision making at Village Medical and Walgreens.</div></div><div><h3>Methods</h3><div>Online simulated cases of patients with diabetes were randomly assigned to PCPs alone or PCP-pharmacist dyad pairs. The patient simulations were administered in 3 seasons in 2023, and participants completed the cases by making care decisions and receiving real-time feedback on improvement opportunities. Care decisions were scored against evidence-based guidelines. In the first season, PCPs completed cases alone to establish a practice baseline. For the next 2 seasons, 40 PCPs were each paired with a pharmacist and asked to complete their next 2 seasons of patient simulations together. Care decisions made by the dyad pairs were compared with 40 Village Medical matched PCPs completing the cases on their own.</div></div><div><h3>Results</h3><div>In the baseline season, we found no difference in the treatment domain between the predyad and control PCPs (64.0% vs. 63.2%, respectively). By the final season, treatment scores improved for both groups (up to 72.9% for the dyads and up to 68.9% for control), a difference-in-difference improvement of +3.2% for the dyads (<em>P</em> = 0.497). Stopping sulfonylureas and prescribing sodium-glucose cotransporter-2 inhibitors showed noteworthy difference-in-difference improvements among the dyads: +16.2% (<em>P</em> = 0.501) and +23.1% (<em>P</em> = 0.296), respectively.</div></div><div><h3>Conclusion</h3><div>This proof-of-concept study provides evidence that PCP-pharmacist collaboration can improve care decisions, especially in polypharmacy management, medication deprescribing, and evidence-based integration of new medications. The results support continued efforts to enhance collaboration between pharmacists and primary care to improve care quality.</div></div>","PeriodicalId":100737,"journal":{"name":"JAPhA Practice Innovations","volume":"2 2","pages":"Article 100031"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143833447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a framework for implementation of pharmacist-led dermatology clinics","authors":"Ruki Wijesinghe","doi":"10.1016/j.japhpi.2025.100038","DOIUrl":"10.1016/j.japhpi.2025.100038","url":null,"abstract":"<div><h3>Background</h3><div>The current landscape of pharmacy practice presents a notable gap for pharmacists specializing in dermatology who seek to establish clinics and specialized services. Unlike other specialized fields, there is a lack of specialized training or specific Board of Pharmacy Specialties certification tailored to dermatology.</div></div><div><h3>Objective</h3><div>This study aimed to explore how entrustable professional activities (EPAs) can revolutionize workplace-based training, addressing specialized needs to evolve the roles of dermatology clinical pharmacists.</div></div><div><h3>Methods</h3><div>A multidisciplinary team of dermatologists, clinical pharmacists, and scholars was formed to create core EPAs and competencies, ensuring high-quality EPA construction through consensus. To align pharmacists’ roles with dermatologists in specialized settings, preliminary EPAs were drafted with a deep understanding of dermatologists’ workflows and pharmacists’ scope of practice.</div></div><div><h3>Results</h3><div>Six core workplace-based EPAs were identified ranging from patient assessment to monitoring. These EPAs, detailed with specific tasks and assessment tools, allowed pharmacists to specialize and efficiently conduct dermatology pharmacist clinics, benefiting patients and the institution. This model’s success led to the sustained operation of dermatology pharmacist clinics, expanding pharmacists’ roles in dermatology subspecialties.</div></div><div><h3>Conclusion</h3><div>A small-scale EPA framework to train clinical pharmacists for independent roles in dermatology clinics was successfully implemented, demonstrating EPAs’ potential to broaden pharmacists’ scope in such settings. This approach provides a model for integrating clinical pharmacists into collaborative teams and can be adapted for training of pharmacists in other specialized settings.</div></div>","PeriodicalId":100737,"journal":{"name":"JAPhA Practice Innovations","volume":"2 2","pages":"Article 100038"},"PeriodicalIF":0.0,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143704192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacist confidence, comfort, and experience screening for and addressing social risks","authors":"Martha Schanandore,&nbsp;Courtney E. Gamston,&nbsp;Lindsey Hohmann,&nbsp;Lena McDowell,&nbsp;Greg Peden,&nbsp;Kimberly Braxton Lloyd","doi":"10.1016/j.japhpi.2025.100033","DOIUrl":"10.1016/j.japhpi.2025.100033","url":null,"abstract":"<div><h3>Background</h3><div>Social determinants of health (SDoH) account for 50%-60% of health outcomes. Pharmacists are uniquely positioned to screen for adverse SDoH (social risks), and address social needs, conditions an individual seeks assistance with immediately. However, previous research has demonstrated that pharmacists lack confidence and experience performing this screening.</div></div><div><h3>Objective</h3><div>This study aimed to assess pharmacist self-perceived knowledge, comfort, and experience screening for SDoH and confidence addressing social needs.</div></div><div><h3>Methods</h3><div>Registered Alabama pharmacists were invited via e-mail to complete an incentivized, anonymous survey. Outcomes were measured via multiple-choice and Likert-type scales, including (1) confidence and comfort with screening and making referrals, (2) current screening and referral activities, (3) awareness of resources, (4) willingness to implement SDoH services, and (5) attitudes regarding SDoH services and were analyzed using descriptive statistics, chi-square analyses, and Pearson correlations.</div></div><div><h3>Results</h3><div>The mean age of the 310 survey participants was 45 ± 9.8 years, and 72% identified as female. Notably, 65% reported working in the community setting; 62% and 65%, respectively, reported a lack of knowledge and ability to identify risks; 84% reported lacking confidence in their ability to address social needs; 55% reported not feeling equipped to use available resources; and 30% indicated currently screening for SDoH at their practice site. Pharmacists identified lack of time (72%) as the most common barrier to screening. Respondents identified lack of resources (65%), personnel (49%), and confidence (32%) and uncertainty of how to link patients to available resources (34%) as other barriers. Most respondents (56%) felt pharmacists could make a positive impact on social risks.</div></div><div><h3>Conclusion</h3><div>Pharmacists reported lack of knowledge, comfort, and experience screening for social risks and barriers to screening for and addressing identified needs. Responses suggest a need for additional training and evaluation of strategies to decrease barriers to SDoH screening and management.</div></div>","PeriodicalId":100737,"journal":{"name":"JAPhA Practice Innovations","volume":"2 2","pages":"Article 100033"},"PeriodicalIF":0.0,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143705903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stronger together: a community case study highlighting the benefits of pharmacy and community collaborations","authors":"Anusha Ban,&nbsp;Ashish Shrestha,&nbsp;Carissa Van-den Berk Clark,&nbsp;Janice Ballard,&nbsp;Richard Logan Jr.,&nbsp;Tripp Logan Sr.,&nbsp;Anne Francioni,&nbsp;Megan Murray,&nbsp;Elizabeth A. Baker","doi":"10.1016/j.japhpi.2024.100024","DOIUrl":"10.1016/j.japhpi.2024.100024","url":null,"abstract":"<div><h3>Background</h3><div>The pandemic exposed weaknesses in existing social and health care infrastructures, disproportionately affecting health outcomes, particularly within rural communities. Addressing these challenges within rural settings requires innovative interventions.</div></div><div><h3>Objective</h3><div>This study seeks to evaluate the role of an interagency network in increasing vaccine uptake in rural settings.</div></div><div><h3>Methods</h3><div>The Network, a partnership of community-based clinical and social service organizations, including community pharmacists, community health workers, and academic researchers, implemented outreach activities which targeted factors related to access to and acceptance of coronavirus disease-2019 vaccines at the individual, interpersonal, community, and environmental levels. Qualitative methods, including in-depth interviews and content analysis of transcripts from planning and networking meetings, were subjected to narrative analysis to document the effectiveness of this multicomponent intervention.</div></div><div><h3>Results</h3><div>Through different outreach efforts, the Network was able to achieve 84,206 educational touchpoints and administer 14,769 vaccines to individuals in the 16-county project area in southeastern Missouri. Leveraging the influence of community pharmacists and community health workers was found to be effective in overcoming barriers to access, improving vaccine uptake, and addressing social and health inequities. Facilitators for the partnership and the success of its initiatives included trust, capacity building, and enhancing access, while poor communication, and unclear role definition created barriers.</div></div><div><h3>Conclusion</h3><div>Study highlights the benefits of community health workers and community pharmacists working collaboratively to increase vaccine uptake in rural Missouri. Findings provide support for expanding this model for future health initiatives.</div></div>","PeriodicalId":100737,"journal":{"name":"JAPhA Practice Innovations","volume":"2 1","pages":"Article 100024"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143177255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improvement in HIV screening follow-up rates with emergency medicine pharmacist counseling and dispensing of postexposure prophylaxis for sexual assault patients","authors":"Kevin A. Kaucher,&nbsp;Nicole M. Acquisto,&nbsp;Eric Gilliam,&nbsp;Katharine Lowrey,&nbsp;Michelle Metz,&nbsp;Jennie Buchanan","doi":"10.1016/j.japhpi.2024.100025","DOIUrl":"10.1016/j.japhpi.2024.100025","url":null,"abstract":"<div><h3>Background</h3><div>Patients presenting to the emergency department (ED) within 72 hours of sexual assault should be offered HIV nonoccupational postexposure prophylaxis (nPEP) and directed to follow-up care. However, low rates of follow-up HIV screening and medication adherence have been consistently found. Strategies to improve these rates have not been universally established.</div></div><div><h3>Objectives</h3><div>To describe improvement in follow-up HIV screening and nPEP medication adherence following emergency medicine (EM) pharmacist involvement in counseling and nPEP dispensing.</div></div><div><h3>Methods</h3><div>This single-center, retrospective, pre-/postimplementation analysis compared rates of sexual assault patient follow-up HIV screening prior to and following initiation of EM pharmacist counseling and dispensing of a 28-day supply of nPEP between January 1, 2016 to December 31, 2016 (preintervention) and January 1, 2017 to December 31, 2019 (postintervention). A telephone survey was administered to identify nPEP medication adherence and related adverse drug event (ADE) rates between August 1, 2018 through August 31, 2019 in the postintervention group.</div></div><div><h3>Results</h3><div>The chart review included 369 unique sexual assault patients prescribed nPEP. The number of patients completing at least one follow-up HIV screening and number of screening occurrences within 6 months of nPEP initiation increased from 3 (3.3%) to 12 (14%) and 4 (1.4%) to 23 (8.9%) from 2016 (preintervention) to 2019 (postintervention), respectively, both <em>P</em> &lt; 0.01. Twenty of 85 patients completed a telephone survey during the postimplementation period. Eight patients (40%) reported completing the 28-day nPEP regimen, and 14 patients (70%) experienced an nPEP-related ADE.</div></div><div><h3>Conclusions</h3><div>EM pharmacist counseling and providing a free complete 28-day supply of nPEP contributed to improved rates of follow-up HIV screening for sexual assault patients after ED discharge.</div></div>","PeriodicalId":100737,"journal":{"name":"JAPhA Practice Innovations","volume":"2 1","pages":"Article 100025"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143177252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}